473 related articles for article (PubMed ID: 33921222)
1. The Influence of Anti-Diabetic Drugs on Prostate Cancer.
Knura M; Garczorz W; Borek A; Drzymała F; Rachwał K; George K; Francuz T
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33921222
[TBL] [Abstract][Full Text] [Related]
2. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
Pratley RE; Salsali A
Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
[TBL] [Abstract][Full Text] [Related]
4. New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies.
Abbatecola AM; Maggi S; Paolisso G
Drugs Aging; 2008; 25(11):913-25. PubMed ID: 18947259
[TBL] [Abstract][Full Text] [Related]
5. Non-insulin antidiabetic therapy in cardiac patients: current problems and future prospects.
Fisman EZ; Motro M; Tenenbaum A
Adv Cardiol; 2008; 45():154-170. PubMed ID: 18230961
[TBL] [Abstract][Full Text] [Related]
6. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
[TBL] [Abstract][Full Text] [Related]
7. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.
Campbell RK
Clin Ther; 2011 May; 33(5):511-27. PubMed ID: 21665040
[TBL] [Abstract][Full Text] [Related]
8. Neurological Manifestation of Incretin-Based Therapies in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
Gao L; Yu S; Cipriani A; Wu S; Huang Y; Zhang Z; Yang J; Sun Y; Yang Z; Chai S; Zhang Y; Ji L; Zhan S; Sun F
Aging Dis; 2019 Dec; 10(6):1311-1319. PubMed ID: 31788342
[TBL] [Abstract][Full Text] [Related]
9. Impact of metabolic disorders on prostate cancer growth: Androgen and insulin resistance perspectives.
Yanase T; Kawanami T; Tanaka T; Tanabe M; Nomiyama T
Reprod Med Biol; 2017 Jul; 16(3):252-257. PubMed ID: 29259475
[TBL] [Abstract][Full Text] [Related]
10. New insights into antidiabetic drugs: Possible applications in cancer treatment.
Shafiei-Irannejad V; Samadi N; Salehi R; Yousefi B; Zarghami N
Chem Biol Drug Des; 2017 Dec; 90(6):1056-1066. PubMed ID: 28456998
[TBL] [Abstract][Full Text] [Related]
11. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials.
Gilbert MP; Pratley RE
Front Endocrinol (Lausanne); 2020; 11():178. PubMed ID: 32308645
[TBL] [Abstract][Full Text] [Related]
12. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
Halimi S
Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
[TBL] [Abstract][Full Text] [Related]
13. Stratified medicine for the use of antidiabetic medication in treatment of type II diabetes and cancer: where do we go from here?
Emami-Riedmaier A; Schaeffeler E; Nies AT; Mörike K; Schwab M
J Intern Med; 2015 Feb; 277(2):235-247. PubMed ID: 25418285
[TBL] [Abstract][Full Text] [Related]
14. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
15. Advances in the treatment of type 2 diabetes mellitus.
Israili ZH
Am J Ther; 2011; 18(2):117-52. PubMed ID: 19834322
[TBL] [Abstract][Full Text] [Related]
16. A review for clinicians: Prostate cancer and the antineoplastic properties of metformin.
Hankinson SJ; Fam M; Patel NN
Urol Oncol; 2017 Jan; 35(1):21-29. PubMed ID: 27836248
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
Penfornis A; Borot S; Raccah D
Diabetes Metab; 2008 Feb; 34 Suppl 2():S78-90. PubMed ID: 18640590
[TBL] [Abstract][Full Text] [Related]
18. Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis.
Zhou JB; Tang X; Han M; Yang J; Simó R
Metabolism; 2020 Aug; 109():154265. PubMed ID: 32446679
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
